Teladoc Health, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $2.5B | $2.6B | $2.6B | $2.4B | $2.0B |
| Operating income | -$263.0M | -$1.0B | -$248.6M | -$13.7B | -$265.6M |
| Cost of revenue | — | — | — | $744.0M | $650.3M |
| Cash from operations | $294.4M | $293.7M | $350.0M | $189.3M | $194.0M |
| Capital expenditure | $8.9M | $10.8M | $11.5M | $16.5M | $8.5M |
| Free cash flow | $285.5M | $282.9M | $338.6M | $172.8M | $185.5M |
| Impairments | $71.8M | $790.0M | $0 | $13.4B | $0 |
| Total assets | $2.9B | $3.5B | $4.4B | $4.3B | $17.7B |
| Total liabilities | $1.5B | $2.0B | $2.1B | — | — |
Shares outstanding 180.5M · Free float 88.2%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.